Organic Letters
Letter
(4) For examples of proposed silanediol anion-binding catalysis, see:
(a) Schafer, A. G.; Wieting, J. M.; Fisher, T. J.; Mattson, A. E. Angew.
Chem., Int. Ed. 2013, 52, 11321−11324. (b) Wieting, J. M.; Fisher, T.
J.; Schafer, A. G.; Visco, M. D.; Gallucci, J. C.; Mattson, A. E. Eur. J.
Org. Chem. 2015, 2015, 525−533.
(5) Kondo, S.; Bie, Y.; Yamamura, M. Org. Lett. 2013, 15, 520−523.
(6) Lee, A. S.-Y.; Chang, Y.-T.; Chu, S.-F.; Tsao, K.-W. Tetrahedron
Lett. 2006, 47, 7085−7087.
Scheme 3. Uses of Benzylic Silanes
(7) Nakamura, M.; Matsumoto, Y.; Toyama, M.; Baba, M.;
Hashimoto, Y. Chem. Pharm. Bull. 2013, 61, 237−241.
(8) Sodner, M.; Sandor, M.; Schier, A.; Schmidbauer, H. Chem. Ber.
1997, 130, 1671−1676.
Pd/C and H2O (eq 1).7 The conversion of 1i to the
chlorosilane, a species now ready for further functionalization,
was achieved with BCl3 and then treated with H2O to yield
silanol 6 in 60% yield (eq 2).8
To conclude, Barbier-type coupling conditions have been
identified as a general strategy for the synthesis of benzylic
silanes. The reaction conditions benefit from being (1)
operationally simple, (2) high yielding, and (3) tolerant of a
broad range of functional groups and sterically encumbered
reaction partners. This new methodology may present a useful
synthetic tactic to enable the construction of more complex
silanes for study as catalysts and reagents, among other things.
ASSOCIATED CONTENT
* Supporting Information
■
S
The Supporting Information is available free of charge on the
General methods, synthetic details, and NMR spectra
AUTHOR INFORMATION
Corresponding Author
■
Present Address
†Vanderbilt Center for Neuroscience Drug Discovery, 393
Nichol Mill Lane, Suite 1000, Franklin, TN 37067.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
We are grateful to the National Science Foundation for
supporting these investigations (Award Number 1362030).
■
REFERENCES
■
(1) For reviews on organosilanols, see: (a) Chandrasekhar, B.;
Boomishankar, R.; Nagendran, S. Chem. Rev. 2004, 104, 5847−5910.
(b) Lickiss, P. D. Adv. Inorg. Chem. 1995, 42, 147−262.
(2) For reviews on organosilanols in drug discovery, see: (a) Sieburth,
S. McN.; Chen, C.-A. Eur. J. Org. Chem. 2006, 2006, 311−322.
(b) Sieburth, S. McN. Advances in Silicon Science; Zelisko, P. M., Ed.;
Springer: Dordrecht, 2014, 103−123. (c) Franz, A. K.; Wilson, S. O. J.
Med. Chem. 2013, 56, 388−405.
(3) For examples of proposed silanediol hydrogen bond donor
catalysis, see: (a) Schafer, A. G.; Wieting, J. M.; Mattson, A. E. Org.
Lett. 2011, 13, 5228−5231. (b) Hardman-Baldwin, A. M.; Mattson, A.
E. ChemSusChem 2014, 7, 3275−3278. (c) Tran, N. T.; Min, T.;
Franz, A. K. Chem. - Eur. J. 2011, 17, 9897−9900.
C
Org. Lett. XXXX, XXX, XXX−XXX